Abbott Launches Next-Generation Detection Technology In the U.S. And Europe

Abbott Launches Next-Generation Detection Technology In the U.S. And Europe

Abbott Launches Next-Generation Detection Technology In the U.S. And Europe

The FINANCIAL -- Abbott this days announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats.

Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable device, combines smartphone connectivity and continuous, remote monitoring to track unpredictable heart rhythm problems for fast and accurate diagnosis.

World's first smartphone-compatible implantable heart monitor, Abbot's confirm Rx™ ICM offers more accurate detection of heart rhythm disorders

An arrhythmia is an abnormal heart rhythm that can lead to symptoms such as the feeling that the heart is racing, dizziness, shortness of breath or fainting. Living with an irregular heartbeat can lead to constant questions for people battling symptoms. For the 33.5 million people living with atrial fibrillation (AFib)—the most common arrhythmia—many do not even know they have the condition.

Abbott's Confirm Rx ICM is helping advance how physicians remotely monitor arrhythmias in people most at risk. Inserted just under the skin in the chest above the heart during a quick, minimally invasive outpatient procedure, the Confirm Rx ICM device is the only ICM on the market that syncs to a smartphone via Bluetooth® and transmits information to the physician to help identify irregular heartbeats quickly. Abbott's mobile app eliminates the need for an additional transmitter and is user-friendly health technology translated in nearly 40 languages.

"Through new advances like Abbott's next generation of Confirm Rx ICM, physicians can act more proactively and efficiently in their treatment approach, and patients can stay engaged and connected," said Avi Fischer, M.D., medical director of Abbott's Cardiac Rhythm Management therapies.

Wearables used to track cardiac arrhythmias have limitations when it comes to making a clinical diagnosis. Many require recharging at night, which can lead to missing irregular heartbeats that may occur sporadically and infrequently. Others require some level of interaction by the person to record symptoms, which may not be top of mind when feeling light headed, dizzy or experiencing a rapid heart rate.

"The rise in health monitoring has undoubtedly increased awareness of arrhythmias such as AFib, but many of these devices still aren't leading to an improved diagnosis or solving the key clinical challenges for people at risk," said Sean Beinart, M.D., a cardiologist with Adventist Healthcare in Rockville, Md. "Like a guardian for heart health, Confirm Rx ICM can relay important data about a person's heart rhythm through their smartphone and alert their care team to a potentially dangerous heart event. With Abbott's new technology, I can better identify risk—making it actionable for me and life-changing for my patient."


Videos

Watch the video